KR20190135500A - 개질된 mri 조영제 및 이의 용도 - Google Patents

개질된 mri 조영제 및 이의 용도 Download PDF

Info

Publication number
KR20190135500A
KR20190135500A KR1020197031523A KR20197031523A KR20190135500A KR 20190135500 A KR20190135500 A KR 20190135500A KR 1020197031523 A KR1020197031523 A KR 1020197031523A KR 20197031523 A KR20197031523 A KR 20197031523A KR 20190135500 A KR20190135500 A KR 20190135500A
Authority
KR
South Korea
Prior art keywords
compound
protein
composition
moiety
mri contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197031523A
Other languages
English (en)
Korean (ko)
Inventor
클레어 엘. 엠. 레가야더
나단 씨. 지안네스키
카산드라 이. 콜먼
매튜 피. 톰슨
트레플리 디트리
폴 에이. 버틴
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
바이빌 홀딩스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아, 바이빌 홀딩스, 인코포레이티드 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20190135500A publication Critical patent/KR20190135500A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
KR1020197031523A 2017-04-27 2018-04-25 개질된 mri 조영제 및 이의 용도 Ceased KR20190135500A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491159P 2017-04-27 2017-04-27
US62/491,159 2017-04-27
PCT/US2018/029271 WO2018200615A2 (en) 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof

Publications (1)

Publication Number Publication Date
KR20190135500A true KR20190135500A (ko) 2019-12-06

Family

ID=63920047

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031523A Ceased KR20190135500A (ko) 2017-04-27 2018-04-25 개질된 mri 조영제 및 이의 용도

Country Status (9)

Country Link
US (1) US20200046859A1 (https=)
EP (1) EP3615088A4 (https=)
JP (1) JP2020517584A (https=)
KR (1) KR20190135500A (https=)
CN (1) CN110582306A (https=)
AU (1) AU2018258345A1 (https=)
CA (1) CA3057976A1 (https=)
SG (1) SG11201908911QA (https=)
WO (1) WO2018200615A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998528A1 (en) * 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011684A1 (de) * 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
JP3404787B2 (ja) * 1993-03-12 2003-05-12 三菱ウェルファーマ株式会社 新規ジエチレントリアミンペンタ酢酸誘導体、該誘導体と金属原子との錯化合物、及び該錯化合物を含む診断剤
AU726914B2 (en) * 1996-04-01 2000-11-23 Epix Pharmaceuticals, Inc. Bioactivated diagnostic imaging contrast agents
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US20030021750A1 (en) * 2001-04-04 2003-01-30 Bakan Douglas A. Novel functional agents for magnetic resonance imaging
JP5291930B2 (ja) * 2005-03-09 2013-09-18 独立行政法人科学技術振興機構 錯化合物及びそれから成るｍｒｉプローブ
WO2008144728A1 (en) * 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications

Also Published As

Publication number Publication date
CN110582306A (zh) 2019-12-17
WO2018200615A3 (en) 2019-01-10
EP3615088A4 (en) 2021-01-27
CA3057976A1 (en) 2018-11-01
US20200046859A1 (en) 2020-02-13
SG11201908911QA (en) 2019-11-28
EP3615088A2 (en) 2020-03-04
AU2018258345A1 (en) 2019-10-17
JP2020517584A (ja) 2020-06-18
WO2018200615A2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
Wang et al. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation
US20050227985A9 (en) Folate mimetics and folate-receptor binding conjugates thereof
CN109982998A (zh) 白蛋白结合psma抑制剂
US20240009314A1 (en) Compositions and methods for targeting tumor-associated macrophages
JP2018527360A (ja) 修飾された細胞毒とその治療的使用
US20250025582A1 (en) Ligands and their use
CN109157662B (zh) 一种人血清白蛋白-阿霉素交联物纳米颗粒及其应用
KR20190135500A (ko) 개질된 mri 조영제 및 이의 용도
US11975077B2 (en) Guanylurea functionalized peptides and proteins for therapeutics
CN111542310A (zh) 包含担载有抗癌剂的纳米结构体作为有效成分的肝癌治疗用药学组合物
WO2018175622A1 (en) Modified anthracycline compounds and their therapeutic use
KR20190123351A (ko) 개질된 올리고뉴클레오티드 및 이의 치료 용도
WO2018175589A1 (en) Modified peptides and uses thereof for treating cancer
HK40019846A (en) Modified mri contrast agents and uses thereof
CN119698299A (zh) 通过放疗的n-氧化物的前药活化
WO2018175601A1 (en) Modified platinum compounds and therapeutic uses thereof
Islam et al. Nanostructured gadolinium (III) micelles: Synthesis, characterization, cytotoxic activities, and MRI applications in vivo
WO2021007322A1 (en) Methods of using modified cytotoxins to treat cancer
WO2018175595A1 (en) Modified histone deacetylase inhibitors and uses thereof
JP3301115B2 (ja) 新規キレート化剤、該キレート化剤と金属原子との錯化合物及びそれを含む診断剤
You et al. A new magnetic resonance imaging probe specifically targeting vascular endothelial growth factor receptor 2: synthesis, characterization and biological evaluation
Morse et al. Melanocortin 1 receptor ligands and methods of use
BR122025011543A2 (pt) Ligantes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191024

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230616

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230823

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230616

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I